Roberto Iacovelli1, Ugo De Giorgi2, Luca Galli3, Paolo Zucali4, Franco Nolè5, Roberto Sabbatini6, Anna Paola Fraccon7, Umberto Basso8, Alessandra Mosca9, Francesco Atzori10, Daniele Santini11, Gaetano Facchini12, Giuseppe Fornarini13, Felice Pasini7, Cristina Masini14, Francesco Massari15, Sebastiano Buti16, Teodoro Sava17, Cosimo Sacco18, Riccardo Ricotta19, Isabella Sperduti20, Giampaolo Tortora21, Camillo Porta22. 1. Department of Medical Oncology, Azienda Ospedaliera Universitaria Integrata, Verona, Italy. Electronic address: roberto.iacovelli@aovr.veneto.it. 2. Department of Medical Oncology, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy. 3. Department of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana and Istituto Toscano Tumori, Pisa, Italy. 4. Humanitas Clinical and Research Center, Humanitas Cancer Center, Rozzano, Italy. 5. Division of Urogenital and Head and Neck Tumours, Department of Medical Oncology, European Institute of Oncology, Milan, Italy. 6. Department of Oncology, Haematology and Radiotherapy, University of Modena and Reggio Emilia, Modena and Reggio Emilia, Italy. 7. Medical Oncology Unit, Casa di Cura Pederzoli, Peschiera del Garda, Verona, Italy. 8. Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto IRCCS, Padua, Italy. 9. Department of Medical Oncology, Maggiore della Carità University Hospital, Novara, Italy. 10. Department of Medical Oncology, Azienda Ospedaliero Universitaria, Cagliari, Italy. 11. Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy. 12. Division of Medical Oncology, Department of Uro-Gynaecological Oncology, Istituto Nazionale Tumori, IRCCS Fondazione G. Pascale, Napoli, Italy. 13. Department of Medical Oncology, IRCCS Azienda Ospedaliera Universitaria San Martino-Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy. 14. Department of Medical Oncology, IRCCS Arcispedale Santa Maria Nuova, Reggio Emilia, Italy. 15. Division of Oncology, Sant'Orsola-Malpighi Hospital, Bologna, Italy. 16. Department of Medical Oncology, University Hospital, Parma, Italy. 17. Department of Oncology, Camposampiero-Cittadella, Padua, Italy. 18. Medical Oncology Unit, Santa Maria Misericordia Hospital, Udine, Italy. 19. Niguarda Cancer Center, Grande Ospedale Metropolitano di Niguarda, Milan, Italy. 20. Biostatistics Unit, Regina Elena National Cancer Institute, Rome, Italy. 21. Department of Medical Oncology, Azienda Ospedaliera Universitaria Integrata, Verona, Italy. 22. Department of Medical Oncology, IRCCS San Matteo University Hospital Foundation, Pavia, Italy.
Abstract
BACKGROUND: The International mRCC (metastatic renal cell carcinoma) Database Consortium (IMDC) is the standard classification for mRCC. We aimed to evaluate the outcomes of a large cohort of patients with an intermediate or a poor prognosis treated with sunitinib using a different cutoff point for IMDC to improve the classification. PATIENTS AND METHODS: Patients with an intermediate or a poor prognosis according to the IMDC criteria and treated with sunitinib were included in the present study. A new cutoff point was used to categorize the patients. The new score was validated in an independent cohort of patients. RESULTS: A total of 457 patients were included in the present study. Significant differences in overall survival (OS) were highlighted regarding the number of prognostic factors. Three categories were identified according to the presence of 1 (ie, favorable-intermediate group), 2 (ie, real-intermediate group), and > 2 (ie, poor group) factors. The corresponding median OS periods were 32.9, 20.0, and 8.9 months, with significant differences among the groups. The validation cohort included 389 patients. The median OS period for the favorable-intermediate group, real-intermediate group, and poor group was 34.3, 19.4, and 9.0 months, respectively, with confirmed significant differences among the groups. CONCLUSION: Our analysis revealed significant differences among patients with an intermediate prognosis using the IMDC prognostic factors. Further investigations to optimize the use of available and upcoming therapies are required.
BACKGROUND: The International mRCC (metastatic renal cell carcinoma) Database Consortium (IMDC) is the standard classification for mRCC. We aimed to evaluate the outcomes of a large cohort of patients with an intermediate or a poor prognosis treated with sunitinib using a different cutoff point for IMDC to improve the classification. PATIENTS AND METHODS: Patients with an intermediate or a poor prognosis according to the IMDC criteria and treated with sunitinib were included in the present study. A new cutoff point was used to categorize the patients. The new score was validated in an independent cohort of patients. RESULTS: A total of 457 patients were included in the present study. Significant differences in overall survival (OS) were highlighted regarding the number of prognostic factors. Three categories were identified according to the presence of 1 (ie, favorable-intermediate group), 2 (ie, real-intermediate group), and > 2 (ie, poor group) factors. The corresponding median OS periods were 32.9, 20.0, and 8.9 months, with significant differences among the groups. The validation cohort included 389 patients. The median OS period for the favorable-intermediate group, real-intermediate group, and poor group was 34.3, 19.4, and 9.0 months, respectively, with confirmed significant differences among the groups. CONCLUSION: Our analysis revealed significant differences among patients with an intermediate prognosis using the IMDC prognostic factors. Further investigations to optimize the use of available and upcoming therapies are required.
Authors: Bernard Escudier; Robert J Motzer; Nizar M Tannir; Camillo Porta; Yoshihiko Tomita; Matthew A Maurer; M Brent McHenry; Brian I Rini Journal: Eur Urol Date: 2019-11-13 Impact factor: 20.096
Authors: Sara Elena Rebuzzi; Luigi Cerbone; Alessio Signori; Matteo Santoni; Veronica Murianni; Ugo De Giorgi; Giuseppe Procopio; Camillo Porta; Michele Milella; Umberto Basso; Francesco Massari; Marco Maruzzo; Roberto Iacovelli; Nicola Battelli; Luca Carmisciano; Giuseppe Luigi Banna; Sebastiano Buti; Giuseppe Fornarini Journal: Ther Adv Med Oncol Date: 2022-02-26 Impact factor: 8.168
Authors: Florian Janisch; Thomas Klotzbücher; Roland Dahlem; Michael Rink; Phillip Marks; Christina Kienapfel; Christian P Meyer; Hang Yu; Constantin Fühner; Tobias Hillemacher; Keiichiro Mori; Hadi Mostafei; Shahrokh F Shariat; Margit Fisch Journal: World J Urol Date: 2021-03-01 Impact factor: 4.226
Authors: Sara Elena Rebuzzi; Alessio Signori; Giuseppe Luigi Banna; Marco Maruzzo; Ugo De Giorgi; Paolo Pedrazzoli; Andrea Sbrana; Paolo Andrea Zucali; Cristina Masini; Emanuele Naglieri; Giuseppe Procopio; Sara Merler; Laura Tomasello; Lucia Fratino; Cinzia Baldessari; Riccardo Ricotta; Stefano Panni; Veronica Mollica; Maria Sorarù; Matteo Santoni; Alessio Cortellini; Veronica Prati; Hector Josè Soto Parra; Marco Stellato; Francesco Atzori; Sandro Pignata; Carlo Messina; Marco Messina; Franco Morelli; Giuseppe Prati; Franco Nolè; Francesca Vignani; Alessia Cavo; Giandomenico Roviello; Francesco Pierantoni; Chiara Casadei; Melissa Bersanelli; Silvia Chiellino; Federico Paolieri; Matteo Perrino; Matteo Brunelli; Roberto Iacovelli; Camillo Porta; Sebastiano Buti; Giuseppe Fornarini Journal: Ther Adv Med Oncol Date: 2021-05-18 Impact factor: 8.168